Research Paper Volume 11, Issue 7 pp 2082—2097

Role of global aberrant alternative splicing events in papillary thyroid cancer prognosis

Peng Lin 1, , Rong-quan He 2, , Zhi-guang Huang 3, , Rui Zhang 3, , Hua-yu Wu 4, , Lin Shi 5, , Xiao-jiao Li 6, , Qing Li 1, , Gang Chen 3, , Hong Yang 1, , Yun He 1, ,

  • 1 Department of Medical Ultrasound, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P. R. China
  • 2 Department of Medical Oncology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P. R. China
  • 3 Department of Pathology, First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi Zhuang Autonomous Region 530021, P. R. China
  • 4 Department of Cell Biology and Genetics, School of Pre-Clinical Medicine, Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
  • 5 Departments of Pathology, Second Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi 530021, P.R. China
  • 6 Departments of PET/CT, the First Affiliated Hospital of Guangxi Medical University, Nanning, P.R. China

received: December 10, 2018 ; accepted: March 31, 2019 ; published: April 15, 2019 ;

https://doi.org/10.18632/aging.101902
How to Cite

Copyright: Lin et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Abstract

Background: Alternative splicing events have been increasingly reported for anomalous perturbations in various cancers, including papillary thyroid cancer (PTC).

Methods: Integration analysis of RNA sequencing and clinical information were utilized to identify survival associated splicing events in PTC. Then, several prognosis-related splicing events were submitted to develop moderate predictors for survival monitoring by using least absolute shrinkage and selection operator model. In addition, several biomedical computational algorithms were conducted to identify pathways enriched by genes with prognostic splicing events and construct regulatory network dominated by splicing factors.

Results: Survival analysis in 496 PTC patients indicated that TNM stage, tumor stage, distant metastasis and tumor status were significantly correlated with PTC patients' progression-free interval. 2799 splicing events were identified as prognostic molecular events. Functional enrichment analysis suggested that prognostic splicing events are associated with several energy metabolism-related processes. Based on these prognostic events, several prognostic signatures were developed. The final prognostic signature acted as an independent prognostic factor after adjusting for several clinical parameters. Interestingly, splicing regulatory network was constructed to display potential regulatory mechanisms of splicing events in PTC.

Conclusions: Our analysis provides the status of splicing events involved in the progression and may represent an underappreciated hallmark of PTC.

Abbreviations

AA: alternate acceptor; AD: alternate donor; AJCC: American Joint Committee on Cancer; AP: alternate promoter; AT: alternate terminator; AS: alternative splicing; ES: exon skip; HR: hazard ration; ME: mutually exclusive exon; PTC: papillary thyroid cancer; PFI: progression-free interval; RI: retained intron; RNA-seq: RNA sequencing; SFs: splicing factors; TCGA: The Cancer Genome Atlas; LASSO: the least absolute shrinkage and selection operator.